The drug industry continued its reign as the top Capitol Hill lobbying group, with a record $168 million in contributions for 2007, a nonpartisan Washington watchdog reported. (BioWorld Today)

WASHINGTON - Firms seeking to gain approval of follow-on biologics (FOBs) should be required by law to conduct clinical trials to demonstrate the products' safety and effectiveness, the Pharmaceutical Research and Manufacturers of American (PhRMA) told a congressional subcommittee. (BioWorld Today)